Glaxo's £1.9bn deal boosts pipeline

GlaxoSmithKline has boosted its pipeline of drugs with a £1.9 billion deal for its American partner on a potential blockbuster medicine.

The proposed acquisition of Human Genome Sciences (HGS) means it has secured the full rights for Benlysta, the first new drug to be approved to treat immune system disease lupus in the US for more than 50 years.